Caveolin-1: a marker for pancreatic cancer diagnosis

References

• Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N. Engl. J. Med.326(7), 455–465 (1992).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin.56(2), 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Melle C, Ernst G, Escher N et al. Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin. Chem.53(4), 629–635 (2007).
   PubMed Web of Science ®Google Scholar
• Jeong S, Lee DH, Lee JI et al. Expression of Ki-67, p53, and K-ras in chronic pancreatitis and pancreatic ductal adenocarcinoma. World J. Gastroenterol.11(43), 6765–6769 (2005).
   PubMed Web of Science ®Google Scholar
• Liao Q, Zhao YP, Yang YC, Li LJ, Long X, Han SM. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat. Dis. Int.6(6), 641–645 (2007).
   PubMed Web of Science ®Google Scholar
• Misek DE, Patwa TH, Lubman DM, Simeone DM. Early detection and biomarkers in pancreatic cancer. J. Natl Compr. Canc. Netw.5(10), 1034–1041 (2007).
   PubMedGoogle Scholar
• Stanton KJ, Sidner RA, Miller GA et al. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am. J. Surg.186(5), 486–492 (2003).
   PubMed Web of Science ®Google Scholar
• Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur. J. Surg. Oncol.33(3), 266–270 (2007).
   PubMed Web of Science ®Google Scholar
• Fujioka S, Misawa T, Okamoto T et al. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J. Hepatobiliary Pancreat. Surg.14(6), 539–544 (2007).
   PubMedGoogle Scholar
• Hess V, Glimelius B, Grawe P et al. CA 19-9 tumor-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol.9(2), 132–138 (2008).
   PubMed Web of Science ®Google Scholar
• Schneider J, Schulze G. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res.23(6D), 5089–5093 (2003).
   PubMedGoogle Scholar
• Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig. Dis. Sci.49(7–8), 1149–1155 (2004).
   PubMed Web of Science ®Google Scholar
• Sandblom G, Granroth S, Rasmussen IC. TPS, CA 19-9, VEGF-A, and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head. Ups. J. Med. Sci.113(1), 102–109 (2008).
   Google Scholar
• Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer85(1), 27–34 (2000).
   PubMed Web of Science ®Google Scholar
• Tonini G, Pantano F, Vincenzi B, Gabbrielli A, Coppola R, Santini D. Molecular prognostic factors in patients with pancreatic cancer. Expert Opin. Ther. Targets11(12), 1553–1569 (2007).
   PubMed Web of Science ®Google Scholar
• Salek C, Benesova L, Zavoral M et al. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World J. Gastroenterol.13(27), 3714–3720 (2007).
   PubMed Web of Science ®Google Scholar
• Ohuchida K, Mizumoto K, Miyasaka Y et al. Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis. J. Pathol.213(3), 275–282 (2007).
   PubMedGoogle Scholar
• Pham NA, Schwock J, Iakovlev V, Pond GR, Hedley DW, Tsao MS. Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. BMC Cancer8(1), 43 (2008).
   PubMedGoogle Scholar
• Yoo SH, Park YS, Kim HR et al. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer42(2), 195–202 (2003).
   PubMedGoogle Scholar
• Liedtke C, Kersting C, Burger H, Kiesel L, Wulfing P. Caveolin-1 expression in benign and malignant lesions of the breast. World J. Surg. Oncol.5, 110 (2007).
   PubMedGoogle Scholar
• Zhu H, Weisleder N, Wu P, Cai C, Chen JW. Caveolae/caveolin-1 are important modulators of store-operated calcium entry in hs578/t breast cancer cells. J. Pharmacol. Sci.106(2), 287–294 (2008).
   PubMedGoogle Scholar
• Timme TL, Satoh T, Tahir SA et al. Therapeutic targets for metastatic prostate cancer. Curr. Drug Targets4(3), 251–261 (2003).
   PubMedGoogle Scholar
• Tahir SA, Ren C, Timme TL et al. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin. Cancer Res.9(10 Pt 1), 3653–3659 (2003).
   PubMed Web of Science ®Google Scholar
• Yang G, Addai J, Wheeler TM et al. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum. Pathol.38(11), 1688–1695 (2007).
   PubMed Web of Science ®Google Scholar
• Wiechen K, Diatchenko L, Agoulnik A et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am. J. Pathol.159(5), 1635–1643 (2001).
   PubMedGoogle Scholar
• Kato K, Hida Y, Miyamoto M et al. Overexpression of caveolin-1 in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer94(4), 929–933 (2002).
   PubMed Web of Science ®Google Scholar
• Hu YC, Lam KY, Law S, Wong J, Srivastava G. Profiling of differentially expressed cancer-related genes in oesophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin. Cancer Res.7(11), 3519–3525 (2001).
   PubMed Web of Science ®Google Scholar
• Cassoni P, Senetta R, Castellano I et al. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas. Am. J. Surg. Pathol.31(5), 760–769 (2007).
   PubMedGoogle Scholar
• Barresi V, Cerasoli S, Paioli G et al. Caveolin-1 in meningiomas: expression and clinico-pathological correlations. Acta Neuropathol.112(5), 617–626 (2006).
   PubMedGoogle Scholar
• Ito Y, Yoshida H, Nakano K et al. Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. Br. J. Cancer86(6), 912–916 (2002).
   PubMedGoogle Scholar
• Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol. Rev.84(4), 1341–1379 (2004).
   PubMed Web of Science ®Google Scholar
• Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am. J. Physiol. Cell Physiol.288(3), C494–C506 (2005).
   PubMed Web of Science ®Google Scholar
• Krajewska WM, Maslowska I. Caveolins: structure and function in signal transduction. Cell. Mol. Biol. Lett.9(2), 195–220 (2004).
   PubMedGoogle Scholar
• Shatz M, Liscowitch M. Caveolin-1: a tumor-promoting role in human cancer. Int. J. Radiat. Biol.84(3), 177–189 (2008).
   PubMed Web of Science ®Google Scholar
• Liu P, Rudick M, Anderson RG. Multiple function of caveolin-1. J. Biol. Chem.277(44), 41295–41298 (2002).
   PubMed Web of Science ®Google Scholar
• Schlegel A, Lisanti MP. A molecular dissection of caveolin-1 membrane attachement and oligomerization. Two separate regions of caveolin-1 C-terminal domain mediate membrane binding and oligomer/oligomer interaction in vivo. J. Biol. Chem.275(28), 21605–21617 (2000).
   PubMedGoogle Scholar
• Glenney JR Jr. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J. Biol. Chem.264(34), 20163–20166 (1989).
   PubMed Web of Science ®Google Scholar
• Glenney JR Jr, Soppet D. Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc. Natl Acad. Sci. USA89(21), 10517–10521 (1992).
   PubMed Web of Science ®Google Scholar
• Li S, Couet J, Lisanti MP. Src tyrosine kinases, Gα subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. J. Biol. Chem.271, 29182–29190 (1996).
   PubMed Web of Science ®Google Scholar
• Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. J. Biol. Chem.272, 30429–30438 (1997).
   PubMed Web of Science ®Google Scholar
• Sowa G, Pypaert M, Sessa WC. Distinction between signaling mechanism in lipid rafts vs. caveolae. Proc. Natl Acad. Sci. USA98(24), 14072–14077 (2001).
   PubMed Web of Science ®Google Scholar
• Sasai K, Kakumoto K, Hanafusa H, Akagi T. The Ras-MAPK pathway downregulates caveolin-1 in rodent fibroblast but not in human fibroblasts: implications in the resistance to oncogene-mediated transformation. Oncogene26(3), 449–455 (2007).
   PubMedGoogle Scholar
• Galbiati F, Volonte D, Engelman JA et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J.17(22), 6633–6648 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang W, Razani B, Altschuler Y et al. Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J. Biol. Chem.275(27), 20717–20725 (2000).
   PubMed Web of Science ®Google Scholar
• Podar K, Anderson KC. Caveolin-1 as a potential new therapeutic target in multiple myeloma. Cancer Lett.233(1), 10–15 (2006).
   PubMed Web of Science ®Google Scholar
• Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol. Cell Biol.23(24), 9389–9404 (2003).
   PubMed Web of Science ®Google Scholar
• Zundel W, Swiersz LM, Garcia A. Caveolin-1 mediated regulation of receptor tyrosine kinase-associated phosphatidyl-inositol 3-kinase activity by ceramide. Mol. Cell Biol.20(5), 1507–1514 (2000).
   PubMed Web of Science ®Google Scholar
• Shack S, Wang XT, Kokkonen GC, Gorospe M, Longo DL, Holbrook NJ. Caveolin-induced activation of the phosphatidylinositol 3-kinase Akt pathway increases arsenite cytotoxicity. Mol. Cell Biol.23(7), 2407–2414 (2003).
   PubMedGoogle Scholar
• Ravid D, Maor S, Werner H, Liscovitch M.Caveolin-1 inhibits cell detachement-induced p53 activation and anoikis by upregulation of insulin-like growth factor-1 receptors and signaling. Oncogene24(8), 1338–1347 (2005).
   PubMedGoogle Scholar
• Mettouchi A, Klein S, Guo W et al. Integrin-specific activation of Rac controls progression through G(1) phase of the cell cycle. Mol. Cell8(1), 115–127 (2001).
   PubMed Web of Science ®Google Scholar
• Forget MA, Desrosiers RR, Del M et al. The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. Clin. Exp. Metastasis19(1), 9–15 (2002).
   PubMed Web of Science ®Google Scholar
• Razani B, Engelman JA, Wang XB et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem.276(41), 38121–38138 (2001).
   PubMedGoogle Scholar
• Galbiati F, Volonte D, Liu J et al. Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. Mol. Biol. Cell12(8), 2229–2244 (2001).
   PubMed Web of Science ®Google Scholar
• Tamaskar I, Choueiri TK, Sercia L, Rini B, Bukowski R, Zhou M. Differential expression of caveolin-1 in renal neoplasms. Cancer110(4), 776–782 (2007).
   PubMed Web of Science ®Google Scholar
• Burgermeister E, Xing X, Rocken C et al. Differential expression and function of caveolin-1 in human gastric cancer progression. Cancer Res.67(18), 8519–8526 (2007).
   PubMedGoogle Scholar
• Galbiati F, Volonte D, Brown AM et al. Caveolin-1 expression inhibits Wnt/β-catenin/Lef-1 signaling by recruiting β-catenin to caveolae membrane domains. J. Biol. Chem.275(30), 23368–23377 (2000).
   PubMed Web of Science ®Google Scholar
• Hulit J, Bash T, Fu M et al. The cyclin D1 gene is transcriptionally repressed by caveolin-1. J. Biol. Chem.275(28), 21203–21209 (2000).
   PubMed Web of Science ®Google Scholar
• Torres VA, Tapia JC, Rodriguez DA et al. Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin. J. Cell. Sci.119(Pt 9), 1812–1823 (2006).
   PubMed Web of Science ®Google Scholar
• Wiechen K, Sers C, Agoulnik A et al. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am. J. Pathol.158(3), 833–839 (2001).
   PubMed Web of Science ®Google Scholar
• Bender FC, Reymond MA, Bron C, Quest AF. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res.60(20), 5870–5878 (2000).
   PubMed Web of Science ®Google Scholar
• Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate46(3), 249–256 (2001).
   PubMed Web of Science ®Google Scholar
• Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am. J. Pathol.161(5), 1647–1656 (2002).
   PubMed Web of Science ®Google Scholar
• Capozza F, Williams TM, Schubert W et al. Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am. J. Pathol.162(6), 2029–2039 (2003).
   PubMed Web of Science ®Google Scholar
• Lee H, Woodman SE, Engelman JA et al. Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase: targeting of dually acylated molecules (GPI-linked, transmembrane, or cytoplasmic) to caveolae effectively uncouples c-Src and caveolin-1 (TYR-14). J. Biol. Chem.276(37), 35150–35158 (2001).
   PubMed Web of Science ®Google Scholar
• Lee H, Park DS, Wang XB, Scherer PE, Schwartz PE, Lisanti MP. Src-induced phosphorylation of caveolin-2 on tyrosine 19. Phospho-caveolin-2 (Tyr(P)19) is localized near focal adhesions, remains associated with lipid rafts/caveolae, but no longer forms a high molecular mass hetero-oligomer with caveolin-1. J. Biol. Chem.277(37), 34556–34567 (2002).
   PubMed Web of Science ®Google Scholar
• Tahir SA, Yang G, Ebara S et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res.61(10), 3882–3885 (2001).
   PubMed Web of Science ®Google Scholar
• Hayashi K, Matsuda S, Machida K et al. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res.61(6), 2361–2364 (2001).
   PubMed Web of Science ®Google Scholar
• Moon KC, Lee GK, Yoo SH et al. Expression of caveolin-1 in pleomorphic carcinoma of the lung is correlated with a poor prognosis. Anticancer Res.25(6C), 4631–4637 (2005).
   PubMedGoogle Scholar
• Fong A, Garcia E, Gwynn L, Lisanti MP, Fazzari MJ, Li M. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am. J. Clin. Pathol.120(1), 93–100 (2003).
   PubMedGoogle Scholar
• Ito Y, Yoshida H, Tomoda C et al. Caveolin-1 and 14-3-3 sigma expression in follicular variant of thyroid papillary carcinoma. Pathol. Res. Pract.201(8–9), 545–549 (2005).
   PubMedGoogle Scholar
• Park SS, Kim JE, Kim YA, Kim YC, Kim SW. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology47(6), 625–630 (2005).
   PubMed Web of Science ®Google Scholar
• Juhasz M, Chen J, Tulassay Z, Malfertheiner P, Ebert MP. Expression of caveolin-1 in gastrointestinal and extraintestinal cancers. J. Cancer Res. Clin. Oncol.129(9), 493–497 (2003).
   PubMedGoogle Scholar
• Murakami S, Miyamoto M, Hida Y et al. Caveolin-I overexpression is a favourable prognostic factor for patients with extrahepatic bile duct carcinoma. Br. J. Cancer88(8), 1234–1238 (2003).
   PubMedGoogle Scholar
• Fine SW, Lisanti MP, Galbiati F, Li M. Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am. J. Clin. Pathol.115(5), 719–724 (2001).
   PubMed Web of Science ®Google Scholar
• Lee H, Volonte D, Galbiati F et al. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol. Endocrinol.14(11), 1750–1775 (2000).
   PubMed Web of Science ®Google Scholar
• Terris B, Blaveri E, Crnogorac-Jurcevic T et al. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am. J. Pathol.160(5), 1745–1754 (2002).
   PubMed Web of Science ®Google Scholar
• Suzuoki M, Miyamoto M, Kato K et al. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br. J. Cancer87(10), 1140–1144 (2002).
   PubMed Web of Science ®Google Scholar
• Tanase C, Mihai M, Ardeleanu C et al. Correlation of Caveolin-1 expression and profileration markers in human pancreatic cancer. Virchows Archiv.451, 379 (2007).
   Google Scholar
• Tanase C, Raducan E, Albulescu L et al. Caveolin-1 expression as a possible biomarker in pancreatic cancer diagnosis. Presented at: Proteomics Europe. Amsterdam, The Netherlands, 4–5 September 2007.
   Google Scholar
• Duxbury MS, Ito H, Ashley SW, Whang EE. CEACAM6 cross-linking induces caveolin-1-dependent, Src-mediated focal adhesion kinase phosphorylation in BxPC3 pancreatic adenocarcinoma cells. J. Biol. Chem.279(22), 23176–23182 (2004).
   PubMed Web of Science ®Google Scholar
• Lin M, DiVito MM, Merajver SD, Boyanapalli M, van Golen KL. Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1. Mol. Cancer4(1), 21 (2005).
   PubMedGoogle Scholar
• Cronogorac-Jurcevic T, Efthimiou E, Nielsen T et al. Expression profiling of microdissected pancreatic adenocarcinomas. 21, 4587–4594 (2002).
   Google Scholar
• van Golen KL. Is caveolin-1 a viable therapeutic target to reduce cancer metastasis? Expert Opin. Ther. Targets10(5), 709–721 (2006).
   PubMed Web of Science ®Google Scholar
• Cordes N, Frick S, Brunner TB et al. Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene26(48), 6851–6862 (2007).
   PubMed Web of Science ®Google Scholar
• Brouet A, DeWever J, Martinive P et al. Antitumor effects of in vivo caveolin gene delivery are associated with the inhibition of the proangiogenic and vasodilatory effects of nitric oxide. FASEB J.19(6), 602–604 (2005).
   PubMedGoogle Scholar
• Bouzin C, Brouet A, De Vriese J, Dewever J, Feron O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J. Immunol.178(3), 1505–1511 (2007).
   PubMed Web of Science ®Google Scholar
• Felley-Bosco E, Bender F, Quest AF. Caveolin-1-mediated post-transcriptional regulation of inducible nitric oxide synthase in human colon carcinoma cells. Biol. Res.35(2), 169–176 (2002).
   PubMedGoogle Scholar
• Burgermeister E, Tencer L, Liscovitch M. Peroxisome proliferator-activated receptor-g upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene22(25), 3888–3900 (2003).
   PubMed Web of Science ®Google Scholar
• Juhasz M, Vertesaljai M, Herszenyi L, Malfertheiner P, Ebert MP, Tulassay Z. The role of caveolin-1 gene in carcinogenesis. Orv. Hetil.145(39), 1985–1989 (2004).
   PubMedGoogle Scholar
• Patlolla JM, Swamy MV, Raju J, Rao CV. Overexpression of caveolin-1 in experimental colon adenocarcinomas and human colon cancer cell lines. Oncol. Rep.11(5), 957–963 (2004).
   PubMed Web of Science ®Google Scholar
• Lin SY, Yeh KT, Chen WT, Chen HC, Chen ST, Chang JG. Promoter CpG methylation of caveolin-1 in sporadic colorectal cancer. Anticancer Res.24(3a), 1645–1650 (2004).
   PubMedGoogle Scholar
• Gao X, Sun Y, Huang L et al. Down-regulation of caveolin-1 in gastric carcinoma and its clinical biological significance. Ai Zheng24(3), 311–316 (2005).
   PubMedGoogle Scholar
• Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane BF. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J. Cell Sci.118(Pt 7), 1493–1503 (2005).
   PubMed Web of Science ®Google Scholar